Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2023 | Addressing leukemic transformation in MDS: ongoing challenges and future outlooks

David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses the importance of addressing leukemic transformation (LT) in myelodysplastic syndromes (MDS), emphasizing the poor outcomes observed in these patients. Dr Sallman then highlights the promise of novel combination approaches being explored in MDS and how these may be a valuable strategy to prevent transformation to acute myeloid leukemia (AML). This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.